June 2, 2014
Astellas Pharma and MSD K.K. have published an interim report of early post-marketing phase vigilance (EPPV) on the sodium-glucose co-transporter-2 (SGLT-2) inhibitor Suglat (ipragliflozin). The companies reported that 133 adverse drug reactions (ADRs) were observed during the period between the...read more